BioSeek, an Asterand company, is improving the success rate of pharmaceutical research and development by integrating human biology from the earliest stages of drug discovery onward. Our BioMAP® Systems incorporate predictive primary human cell-based disease models that generate uniquely informative biological activity profiles for each potential drug. As a result, our technology drives the selection and development of new drug candidates. We leverage our BioMAP® Systems technology in collaborations to enhance the productivity of our pharmaceutical partners' pipelines to identify promising compounds for therapeutic development.
Asterand subsidiary achieves “research milestone” with Japanese partner
Human tissue specialist Asterand (LON:ATD) announced today that its BioSeek subsidiary has achieved a “research milestone” in its drug discovery collaboration with Japanese pharmaceutical firm Ono Pharmaceutical.
BioSeek is applying its BioMAP platform to perform a number of tasks on a drug discovery target selected by Ono. These tasks include phenotypic screening, hit identification, lead optimisation and clinical candidate selection.
Under the three-year agreement with Ono, BioSeek is receiving research funding and is eligible to receive success payments based on the research-phase progress of this collaboration and further milestone payments based on the clinical development-phase progress of a drug candidate discovered under this collaboration. Ono will have worldwide rights to develop and sell all pharmaceutical products discovered through the collaboration.
“We highly value our relationship with Ono since it enables us to take full advantage of BioMAP'’s power to discover and develop innovative new drug candidates,” said Jack Davis, Asterand’s chairman and chief executive officer. “We are looking forward to the successful continuation and further achievements of the collaboration.”
Asterand is a supplier of high-quality human tissue and tissue-based services. It takes a “comprehensive approach” to human tissue and associated research services, which it says offers pharmaceutical, biotech and diagnostic companies a “unique opportunity” to have one company meet all of their human biomaterial needs.